---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-039225"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:27:45.772946+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cytek Biosciences Q4 rev $57.5M (-1.3%); FY24 net loss $6.0M; guides FY25 rev $204-212M

## Summary
- Full year 2024 revenue $200.5M (+3.9% YoY); Q4 revenue $57.5M (-1.3% YoY, +1.4% constant currency).
- Net loss improved to $6.0M from $12.1M in 2023; adjusted EBITDA $22.4M (+77% YoY).
- Installed base reached 3,034 instruments; 667 placed in 2024.
- Board authorized new $50M stock repurchase program for 2025; $21.6M repurchased in 2024.
- 2025 revenue guidance $204-212M (2-6% growth); opened Singapore manufacturing facility.

## SEC filing metadata
- accession: 0001193125-25-039225
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312525039225/0001193125-25-039225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312525039225/d829130d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-039225
- JSON: https://secwatch.observer/filing/0001193125-25-039225.json
- Plain text: https://secwatch.observer/filing/0001193125-25-039225.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.